
    
      This is a randomized, double-blind, placebo-controlled, single ascending dose, single site,
      interventional study. There will be 5 single ascending dose (SAD) IV cohorts and 1 SC cohort.
      Nine participants will be enrolled into each of 5 IV cohorts and 1 SC cohort and participants
      will be randomized at a ratio of 2:1 to receive JNJ-61178104 or placebo. The total duration
      of participants participation will be approximately 21 weeks including a Screening Visit up
      to 4 weeks prior to study drug administration. Participants will have an inpatient period
      consisting of 6 days/5 nights and will return to the study-site at Weeks 2, 3, 4, 5, 7, 9,
      13, and 17. Participants will be evaluated for safety throughout the study.
    
  